tbuckley/cabot-search huggingface dataset:
Vale: Sir Francis Avery Jones.
Journal: Gut (1978)

it was agreed that the first number should include a Foreword written by the Editor, Mr Harold Edwards, but that 'subsequent issues contain no editorial because this feature was a difficult one to maintain'.In this issue, however, we have decided to include an Editorial because this is the first issue of Gut to appear since its inception without the active partici- pation of Sir Francis Averv Jones.Sir Francis was intimately involved in the foundation ofthe journal in 1960 and then became the first Editorial Secretary, a position comparable with that of the Editor today.After five years he became Editor, holding that office until 1970.Sir Francis was also involved in christening the journal with its short and effective Anglo-Saxon name.Since 1968, he has edited the Notes and Activities section of Gut, and he has recently introduced and edited the Book Reviews.He has therefore been associated with the journal foi 18 years, a period during which his visits to the editorial office have brought pleasure and delight to all those who have had the privilege of working with him.It has also been a period of almost logarithmic growth of gastroenterology.In 1960, the first issue of Gut recorded the
Why Obesity?
Authors: George A. Bray
Journal: Annual Review of Nutrition (2015)

As Erwin Chargaff observed, “Scientific autobiography belongs to a most awkward literary genre,” and mine is no exception. In reviewing my scientific life, I contrast the nutritional influences that would have existed had I been born 100 or 200 years earlier than I actually was. With this background, I trace the influences on my formative years in science beginning in high school and ending as a postdoctoral fellow in Professor E.B. Astwood's laboratory, when my directional sails were set and obesity was the compass heading. With this heading, the need for organized national and international meetings on obesity and the need for a scientific journal dealing with obesity as its subject matter became evident and occupied considerable energy over the next 30 years. The next section of this memoir traces the wanderings of an itinerant academic who moved from Boston to Los Angeles and finally to Baton Rouge. The influence of Sir William Osler's idea that there is a time for education, a time for scholarship, a time for teaching, and time to retire has always been a guide to allocating time ever since I was an intern at Johns Hopkins Hospital. It was in Baton Rouge that the final phase began: I agreed to become the first full-time executive director of the Pennington Biomedical Research Center, a decision that changed my life. The article ends with a quotation from Tennessee Williams that reflects the theater, which has given me so much pleasure over the years: “There is a time for departure even when there's no certain place to go.”
American Medical History
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Duplex Ultrasonography in Temporal Arteritis
Authors: Carlo Salvarani, Angelo Ghirarduzzi, Luigi Boiardi
Journal: Annals of Internal Medicine (2003)

Letters1 April 2003Duplex Ultrasonography in Temporal ArteritisCarlo Salvarani, MD, Angelo Ghirarduzzi, MD, and Luigi Boiardi, MD, PhDCarlo Salvarani, MDArcispedale S. Maria Nuova; 42100 Reggio Emilia, Italy (Salvarani, Ghirarduzzi, Boiardi)Search for more papers by this author, Angelo Ghirarduzzi, MDArcispedale S. Maria Nuova; 42100 Reggio Emilia, Italy (Salvarani, Ghirarduzzi, Boiardi)Search for more papers by this author, and Luigi Boiardi, MD, PhDArcispedale S. Maria Nuova; 42100 Reggio Emilia, Italy (Salvarani, Ghirarduzzi, Boiardi)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-7-200304010-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:In our study, we found that ultrasonographic evidence of a dark halo (in particular a halo of 1 mm) around the lumen of the temporal arteries had good specificity (93%), but low sensitivity (40%). In other words, the presence of halo ruled in a diagnosis of giant-cell arteritis but its absence did not exclude it. Schmid and colleagues (1) recently found that the halo sign had a sensitivity of 50% and a specificity of 100% for diagnosing giant-cell arteritis. As in our study, all of their patients were prospectively examined, had temporal artery biopsy, and underwent ultrasonography before ...References1. Schmid R, Hermann M, Yannar A, Baumgartner RW. [Color duplex ultrasound of the temporal artery: replacement for biopsy in temporal arteritis]. Ophthalmologica. 2002;216:16-21. [PMID: 11901283] CrossrefMedlineGoogle Scholar2. Schmidt WA, Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology Oxford. 2002;41:46-52. [PMID: 11792879] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Arcispedale S. Maria Nuova; 42100 Reggio Emilia, Italy (Salvarani, Ghirarduzzi, Boiardi) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoIs Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis? Carlo Salvarani , Mauro Silingardi , Angelo Ghirarduzzi , Giovanni Lo Scocco , PierLuigi Macchioni , GianLuigi Bajocchi , Marco Vinceti , Fabrizio Cantini , Ido Iori , and Luigi Boiardi Duplex Ultrasonography in Temporal Arteritis Wolfgang A. Schmidt and Erika Gromnica-Ihle Metrics Cited ByUltrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis 1 April 2003Volume 138, Issue 7Page: 609-610KeywordsArteriesBiopsyElderlyLesionsPolymyalgia rheumaticaSigns and symptomsSpecificityStenosisTemporal arteritisUltrasound imaging ePublished: 1 April 2003 Issue Published: 1 April 2003 CopyrightCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Osteomyelitis in Crohn's Disease: Diagnostic Assessment
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer.
Authors: Sun Jin Sym, Junsik Hong, Minkyu Jung, Yang Seo Koo, Yeon Ho Park, Koen Kook Kim, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Dongbok Shin
Journal: Journal of Clinical Oncology (2012)

344 Background: Treatment with single agent gemcitabine provides modest benefits in patients with metastatic pancreatic cancer. This study was performed to determine the efficacy of gemcitabine in combination with oxaliplatin and capecitabine in patient with recurrent or metastatic pancreatic adenocarcinoma. Methods: This was a prospective, single-arm, single center study in patients with chemotherapy-naive metastatic or recurrent pancreatic adenocarcinoma. The primary endpoint was objective response. The study was designed as a Simons two-stage optimal design and was divided into two stages. The first stage was to recruit up to 18 patients. If at least two objective responses were obtained, then a further 25 patients would be enrolled into the study. If no more than two responses were obtained among these 18 patients, the study would be halted. The study patients received gemcitabine 800 mg/m 2 , plus oxaliplatin 100 mg/m 2 and capecitabine 800 mg/m 2 /day on days 1-7 every 14 days. Treatment was to be administered until disease progression or until withdrawal from the study due to unacceptable toxicity or other reasons. Results: Eighteen patients were enrolled. Median age was 63 years (range, 39-73 years). Among these 18 patients, only one patient (5.5%) achieved an objective response. Therefore, the accrual terminated. The median time to disease progression was 2.1 months, and the median overall survival duration was 4.9 months. One-year overall survival rates were 35.3%. The most frequently reported grade 3 or 4 adverse events were asthenia (16.6%), and nausea (5.5%). There were no unexpected toxicities. Conclusions: The addition of oxaliplatin and capecitabine to gemcitabine did not improve objective response in the first-line treatment of advanced pancreatic cancer patients.
Postmarketing follow-up: physicians have key role
Authors: M. F. Goldsmith
Journal: JAMA (1985)

Each year in the United States, 1.6 billion new and renewal prescriptions for drugs—approximately eight per person—are written, says Gerald A. Faich, MD, director of the FDA's Office of Epidemiology and Biostatistics. Most of these prescriptions are for older, established drugs, but about 20 new chemical entities come into the marketplace annually. "People must understand that everything that goes into the multimillion dollar package of getting a drug through FDA approval cannot be totally complete," Faich emphasizes. "Clinical trials go on for only a couple of years; there are inherent limitations [on time, size, cost, and inclusion of other complicating factors]. Once a drug is on the market, that's where we come in. Our task is postmarketing surveillance, and our division [of the Center for Drugs and Biologics] is probably the one with which physicians are likely to be in contact." "We know that most of what we're going to
THE LUST OF SLANDER.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PWE-234 Optimising the response to thiopurine therapy: a search for novel explanations for thiopurine hypermethylation
Authors: P A Blaker, A M Peters van Ton, M Arenas Hernandez, M A Smith, C H Smith, P Irving, A M Marinaki, J D Sanderson
Journal: Gut (2012)

<h3>Introduction</h3> Thiopurines are not effective in up to 1/3 of patients with inflammatory bowel disease (IBD) and 1/5 have to discontinue therapy due to side effects. An important cause of these problems is thiopurine hypermethylation. This is a catabolic process leading to an unfavourable thiopurine metabolite profile (high methyl-mercaptopurine (MeMP) to low thioguanine nucleotide (TGN) ratio; &gt;11:1), which cannot be predicted by measurement of thiopurine-<i>S</i>-methyltransferase (TPMT) activity. Importantly thiopurine hypermethylation can be circumvented with the use allopurinol in combination with a low dose thiopurine. The aim of this study is to establish the mechanism of thiopurine hypermethylation and identify predictive genetic markers to allow early combination therapy. We hypothesised that thiopurine hypermethylation occurs as a result of genetic factors that affect methylation flux and the cellular transport of methylated metabolites. <h3>Methods</h3> 168 age and dose-matched patients prescribed AZA/6-MP were identified. Genomic DNA was extracted from EDTA blood samples of 76 patients demonstrating thiopurine hypermethylation and 92 patients with normal methylation profiles. Polymorphic sequence variants in genes predicted to affect thiopurine methylation flux and cellular metabolite transport were identified from single nucleotide polymorphism (SNP) databases and genotyped by Taqman assay. Associations were tested using Fisher9s Exact test. <h3>Results</h3> We found a significant association between the haplotype of rs9332377 T and rs4646316 C, which encodes a low-activity synonymous Catechol-O-methyltransferase (COMT) variant, and protection from thiopurine hypermethylation (rs9332377 T, p=0.0178, rs4646316 C, p=0.03). A polymorphism in the nucleo-base transporter, ABCB5, was significantly associated with thiopurine hypermethylation (rs2031641 G/G, p=0.0098). The association was strengthened when patients with MeMP levels &gt;5000 pmol/l vs MeMP &lt;5000 pmol/l were compared (p=0.0065). <h3>Conclusion</h3> Changes in methylation flux due to the activity of methyltransferases other than TPMT affect the formation of thiopurine methylated metabolites, likely through direct competition for the essential co-factor S-adenosylmethionine. Furthermore, polymorphism in the ABCB5 gene, which affects the nucleotide-binding domain of this transporter, is associated with thiopurine hypermethylation, suggesting reduced cellular efflux of methylated metabolites. Further studies are now indicated to establish the role of these genetic markers in clinical practice. <h3>Competing interests</h3> None declared.
Notions Pratiqus D'Électrothérapie Appliquée a l'Urologie.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of contents
Journal: Hepatology (2019)

Cover Figure: Advanced whole-body composition analysis with MRI in a representative patient from the ARRIVE trial.Changes from week 0 to week 12 in visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT) were 4.38 to 4.78 L and 7.67 to 7.88 L, respectively.Week 0 to week 12 total thigh muscle volume change was 12.47 to 12.75 L.
ETHER DAY.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NECROLOGY
Authors: F. D. Cunningham
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viral hepatitis among American missionaries abroad. A preliminary study
Authors: A. I. Cline
Journal: JAMA (1967)

It is the impression of many physicians that the incidence of viral hepatitis among Americans abroad is much higher than that in the United States. There is very little information available, however, to assist them in determining whether this is indeed true. Attack rates have only been determined for military populations, and may not apply to civilians who obviously live under very different circumstances. To assess the extent to which viral hepatitis is a risk, a group is needed which has been under medical supervision while residing in countries thought to be "hyperendemic." American missionaries and their families are such a group, and seem to be a suitable population in many respects. They remain abroad for long periods of time, work in close contact with the indigenous populations, and in general have not received immune globulin for prevention of infectious hepatitis. Accordingly, in October 1964 the present study was undertaken.
Medical-legal aspects of curbside consultation
Authors: B. C. Fox
Journal: JAMA (1996)

<h3>In Reply.</h3> —We appreciate the comments of Dr Fox and share his concern regarding the potential for the current managed care environment to redefine physicians' duty of care to include situations outside the traditional physician-patient relationship. Specifically, we also are concerned about the possibility that a consultant under contract with a managed care organization may be subject to litigation by giving informal advice to another participating physician regarding the care of a patient enrolled in the same plan. Fortunately, the circumstances of the case cited by Fox<sup>1</sup>were sufficiently different than those surrounding most curbside consultations that the verdict in favor of the plaintiff cannot be invoked to encourage future litigation involving consultants who give informal advice to their colleagues. First, the defendant was the de facto assigned primary caregiver (not a consultant) for the plaintiff under the health care plan agreement. Second, as the gatekeeper, the defendant implicitly assumed major
Assessment of Undervaccinated Children Following a Mass Vaccination —Kansas, 1993
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal